Roivant Shares Rise 8.1% After Positive Phase 3 Uveitis Results
Roivant shares gained 8.1% to $37.74 in premarket trading after positive phase 3 trial results for a treatment for non-infectious uveitis.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.